These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16040383)

  • 1. Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility.
    Davis-Sproul JM; Harris MP; Davidson NE; Kobrin BJ; Jaffee EM; Emens LA
    Cytotherapy; 2005; 7(1):46-56. PubMed ID: 16040383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells.
    Kim TS; Jung MY; Cho D; Cohen EP
    Vaccine; 2006 Oct; 24(42-43):6564-73. PubMed ID: 16837111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.
    Simmons AD; Li B; Gonzalez-Edick M; Lin C; Moskalenko M; Du T; Creson J; VanRoey MJ; Jooss K
    Cancer Immunol Immunother; 2007 Oct; 56(10):1653-65. PubMed ID: 17410360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.
    Jaffee EM; Schutte M; Gossett J; Morsberger LA; Adler AJ; Thomas M; Greten TF; Hruban RH; Yeo CJ; Griffin CA
    Cancer J Sci Am; 1998; 4(3):194-203. PubMed ID: 9612602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor.
    Driessens G; Hamdane M; Cool V; Velu T; Bruyns C
    Cancer Res; 2004 Nov; 64(22):8435-42. PubMed ID: 15548715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.
    Inoue H; Iga M; Nabeta H; Yokoo T; Suehiro Y; Okano S; Inoue M; Kinoh H; Katagiri T; Takayama K; Yonemitsu Y; Hasegawa M; Nakamura Y; Nakanishi Y; Tani K
    Cancer Sci; 2008 Nov; 99(11):2315-26. PubMed ID: 18957055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats.
    Djalilian HR; Caicedo E; Lessan K; Grami V; Le CT; Spellman SR; Pambuccian S; Hall WA; Low WC; Ondrey FG
    Cancer Immunol Immunother; 2007 Aug; 56(8):1207-14. PubMed ID: 17219150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats.
    Chen JC; Chen Y; Wu JM; Su YH; Tai KF; Tseng SH
    Cancer Immunol Immunother; 2006 Jul; 55(7):873-83. PubMed ID: 16133106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
    Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
    Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma.
    Ohashi K; Kobayashi G; Fang S; Zhu X; Antonia SJ; Krieg AM; Sandler AD
    J Pediatr Surg; 2006 Aug; 41(8):1361-8. PubMed ID: 16863838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF.
    Yuan S; Shi C; Han W; Ling R; Li N; Wang T
    Eur J Cancer Prev; 2009 Sep; 18(5):416-23. PubMed ID: 19550341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors.
    Gulen D; Abe F; Maas S; Reed E; Cowan K; Pirruccello S; Wisecarver J; Warkentin P; Northam M; Turken O; Coskun U; Senesac J; Talmadge JE
    Int Immunopharmacol; 2008 Dec; 8(13-14):1728-36. PubMed ID: 18793758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1.
    Gravekamp C; Leal B; Denny A; Bahar R; Lampkin S; Castro F; Kim SH; Moore D; Reddick R
    Cancer Immunol Immunother; 2008 Jul; 57(7):1067-77. PubMed ID: 18094967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
    Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V
    Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
    Higano CS; Corman JM; Smith DC; Centeno AS; Steidle CP; Gittleman M; Simons JW; Sacks N; Aimi J; Small EJ
    Cancer; 2008 Sep; 113(5):975-84. PubMed ID: 18646045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of anti-tumor immunity by lyophilized myeloma cells secreting GM-CSF.
    Wu S; Yuan D; Liu JN; Tan XY
    Oncol Rep; 2007 Jan; 17(1):129-33. PubMed ID: 17143489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2.
    Uemura Y; Kobayashi M; Nakata H; Kubota T; Saito T; Bandobashi K; Taguchi H
    Oncol Rep; 2007 Apr; 17(4):955-61. PubMed ID: 17342342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.